Xilio Announces Phase 2 Data for Vilastobart in Metastatic Colorectal Cancer
Xilio Therapeutics announced initial positive Phase 2 data for vilastobart (XTX101), a tumor-activated anti-CTLA-4 antibody, combined with atezolizumab (Tecentriq®)...
ACTG Launches Second HIV Cure Trial in Africa
The AIDS Clinical Trials Group (ACTG) launched the ACACIA study, a Phase 2 trial investigating the use of two...
RS Biotherapeutics Sees Positive Effects of Lead Compound on Human Lung Tissue
RS BioTherapeutics announced positive results from a human lung tissue study of its lead compound, RSBT-001. The study showed...
Nacuity Gets FDA Fast Track for Retinitis Pigmentosa Treatment
Nacuity Pharmaceuticals has received FDA Fast Track designation for NPI-001, an investigational treatment for retinitis pigmentosa (RP). This designation...
Ropidoxuridine Shows Promise in Glioblastoma Trial
Shuttle Pharmaceuticals has reached 25% enrollment in the initial randomized portion of its Phase 2 clinical trial for Ropidoxuridine...
Mainz Biomed starts a next-generation clinical trial for adenoma detection
Mainz Biomed NV launched eAArly DETECT 2, a U.S. feasibility study for its next-generation colorectal cancer (CRC) screening test....
Humacyte Plans IND Filing for Small-Diameter ATEV™ in 2025
Humacyte plans to submit an Investigational New Drug (IND) application to the FDA for its small-diameter (3.5mm) acellular tissue...
AI in Oncology to Hit $11.52B by 2030, with 29.4% CAGR
The global AI in oncology market, valued at US$1.92 billion in 2023, is projected to reach US$11.52 billion by...
Datroway® Approved for Metastatic Breast Cancer
Datopotamab deruxtecan (DATROWAY), a TROP2-directed antibody-drug conjugate (ADC), has received US approval for treating adults with unresectable or metastatic...
FDA Accepts Arrowhead’s New Drug Application for Plozasiran Treatment
Arrowhead Pharmaceuticals announced that the FDA accepted its New Drug Application (NDA) for plozasiran, a treatment for the rare...